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A B S T R A C T
Background: This study aimed to evaluate the association between left atrial (LA) structural remodeling
and very late recurrence [VLR; initial recurrence >12 months after catheter ablation (CA)] after
successful CA for non-paroxysmal atrial ﬁbrillation (AF).
Methods: We retrospectively evaluated 63 patients who underwent initial, single ablation for drug-
refractory persistent or long-standing persistent AF and those who had no recurrence in the ﬁrst year
after CA. We followed patients for a mean of 3.2  1.5 years and divided them into VLR and no-recurrence
(NR) groups. Before and 3 months after ablation, all patients were subjected to 64-slice multidetector
computed tomography scanning to estimate LA volume, including maximum and minimum volume during
the cardiac cycle (LAMaxV and LAMinV, respectively), and the LA emptying fraction.
Results: VLR occurred in 21 patients. The reduction rate of LAMaxV after CA was signiﬁcantly larger in
the NR group than in the VLR group (25  19% vs. 5  18%, p = 0.0002). Receiver operating characteristic
analysis was performed to determine the best cut-off values in the prediction of VLR. The highest area-under
curve was obtained with post-CA LAMinV [0.828 (95% conﬁdence interval, 0.712–0.912), p < 0.0001], with a
best cut-off value of 44 mL (sensitivity 81.0%, speciﬁcity 81.0%).
Conclusions: Persistent LA structural remodeling after initially successful CA for non-paroxysmal AF may
be an important risk factor for VLR.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Radiofrequency catheter ablation (RFCA) is reportedly more
efﬁcacious than drug therapy in restoring sinus rhythm in patients
with atrial ﬁbrillation (AF) [1–3]. However, despite advances in
ablation techniques, AF recurrence is common and a signiﬁcant
number of patients require repeat procedures. AF recurrence is* Corresponding author at: Department of Cardiology, Sakurabashi-Watanabe
Hospital, 2-4-32, Umeda, Kita-ku, Osaka 530-0001, Japan. Tel.: +81 6 6341 8651;
fax: +81 6 6341 0785.
E-mail address: koichi@inoue.name (K. Inoue).
http://dx.doi.org/10.1016/j.jjcc.2015.03.007
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsdivided into three types: early recurrence (ER: AF recurrence
during the ﬁrst 3 months after initial RFCA, i.e. the blanking
period), late recurrence (LR: AF recurrence 3–12 months after
initial RFCA), and very late recurrence (VLR: AF recurrence >1 year
after initial RFCA). LR is mainly caused by electrical pulmonary vein
(PV) reconnection [4,5]; on the other hand, we previously reported
that VLR might be caused by the progression of AF substrates and
generation of non-PV triggers [6,7].
The progression of structural remodeling is easily identiﬁed as
left atrial (LA) enlargement, which is the surrogate marker for AF
substrates. Because LA reverse remodeling can occur during
short-term follow-up after sinus conversion by RFCA [8–14], it is
possible that patients without sufﬁcient reverse remodeling after reserved.
Y. Sotomi et al. / Journal of Cardiology 66 (2015) 370–376 371successful RFCA have residual LA substrate, which might cause
subsequent VLR.
This study aimed to evaluate the association between post-
RFCA reverse remodeling and VLR during long-term follow-up
after successful RFCA for non-paroxysmal AF.
Methods
Study design
The study design was a retrospective, single-center, case–
control study. A pre-study power analysis indicated that a sample
size of 56 patients was necessary as described below. A total of
293 patients with drug-refractory non-paroxysmal AF underwent
initial, single RFCA at Sakurabashi-Watanabe Hospital between
2006 and 2010. Among these patients, 114 patients were still
under follow-up in January 2014. In this patient population, we
enrolled 42 and 21 patients with sufﬁcient data set who
experienced no recurrence (NR) and VLR, respectively. The other
51 patients include ER patients, LR patients, or NR and VLR patients
with insufﬁcient data set. Patients with ER and LR were not
evaluated in this study. Final follow-up was performed in January
2014. Written informed consent for the ablation was obtained
from all patients. The study protocol was approved by the
institution’s ethic committee.
Before the ablation procedure and after 3 months of follow-up,
multidetector computed tomography (MDCT) was performed to
assess LA reverse remodeling. Before the procedure, MDCT was
performed during AF rhythm for all patients, and we assessed
the LA maximum and minimum volume (pre-LAMaxV and pre-
LAMinV, respectively) and LA emptying fraction [pre-LAEF;
deﬁned as (LAMaxV  LAMinV)/LAMaxV  100]. Three months
after RFCA, the same parameters were reassessed during sinus
rhythm (post-LAMaxV, post-LAMinV, and post-LAEF). We retro-
spectively evaluated the association between these LA functional
parameters and VLR.
Clinical variables
We analyzed the following clinical variables: age, gender, height,
weight, body mass index (BMI), patient history [long-standing
persistent AF (duration of non-paroxysmal AF), hypertension,
diabetes mellitus, dyslipidemia, and obesity (deﬁned as BMI
25 kg/m2)], CHADS2 score (C, congestive heart failure; H,
hypertension; A, age 75 years; D, diabetes mellitus; and S, stroke),
laboratory data [high sensitive C-reactive protein (hsCRP), estimated
glomerular ﬁltration rate, brain natriuretic peptide (BNP)], trans-
thoracic echocardiography data (left ventricular diastolic and
systolic dimensions, LA diameter, left ventricular ejection fraction,
and mitral annulus velocity), computed tomography data (LAMaxV,
LAMinV, and LAEF), and follow-up period. AF was categorized into
three types: paroxysmal (AF terminated spontaneously within
7 days), persistent (AF episodes for more than 7 days or AF requiring
termination by cardioversion), and longstanding persistent (AF
lasting for more than 1 year). Both persistent AF and longstanding
persistent AF were deﬁned as non-paroxysmal AF; only these were
evaluated in the present study.
Scan protocol and data acquisition of MDCT
MDCT was performed within 1 week before and 3 months after
ablation. A 64-slice MDCT scanner (Brilliance CT 64, Philips
Medical Systems, Cleveland, OH, USA) was used with the following
parameters: collimation, 64  0.625 mm; gantry rotation time,
420 ms; effective tube current, 800–1200 mA (higher values in
obese patients); and tube voltage, 120 kV. The scan technique wasdeﬁned by the attending physician in charge. A bolus of nonionic
iodinated contrast (Iopamirone 370, Bayer, Osaka, Japan) was
injected through an antecubital vein at a ﬂow rate of
0.67 mL/min/kg for 15 s, followed by a saline bolus ﬂush. The
scan was initiated according to the bolus-tracking method [6 s
after the threshold of 120 Hounsﬁeld units in the descending
aorta]. Cardiac images from the carina to the apex of the heart were
acquired during one breath-hold.
Using the Comprehensive Cardiac Analysis software on Extended
Brilliance Workspace (ver. 4.5.5.5; 1035 Philips Medical Systems),
LAMaxV and LAMinV in one cardiac cycle were automatically
measured using a volumetric segmentation method (the contour
detection was visually checked and manually corrected if considered
necessary), and LAEF was calculated as mentioned earlier.
Electrophysiological study and RFCA
A 6-French (Fr) decapolar catheter was placed in the coronary
sinus via the median antebrachial vein, while a 7-Fr decapolar
catheter was placed in the superior vena cava and right atrium via
the femoral vein. Three long sheaths were introduced into the left
atrium using a single transseptal puncture technique. An initial
intravenous bolus of heparin (150 IU/kg) was followed by
continuous infusion to maintain an activated clotting time of
>300 s. Pulmonary angiography was performed by injecting a
contrast medium through the transseptal long sheaths into the left
atrium. Electrical cardioversion was performed in all cases.
PV isolation was guided by either ﬂuoroscopy or three-
dimensional mapping. We used an ablation catheter with an 8-
mm tip (Fantasista, Japan Lifeline Co., Ltd., Tokyo, Japan) before
December 2009 and an irrigated ablation catheter with a 3.5 mm
tip (Navistar THERMOCOOL, Biosense Webster, Diamond Bar, CA,
USA) after January 2010 for mapping and ablation. All patients
underwent extensive PV isolation using the double lasso tech-
nique. Radiofrequency energy was delivered for 30 s at each point:
up to 30 W, with a temperature limit of 43 8C, or up to 35 W, with a
temperature limit of 50 8C, when using an irrigated or non-
irrigated catheter, respectively. CA was performed using a
conventional electrophysiological and anatomical approach. Cir-
cumferential PV isolation (deﬁned as abolition or dissociation of PV
potentials) was successfully performed in all patients. We also
attempted to ablate non-PV premature atrial contractions if they
triggered AF or appeared frequently, and targeted atrial ﬂutter
coexisting with atrial tachycardia. If it was difﬁcult to maintain
sinus rhythm, we performed isolation of the superior vena cava,
linear ablation of the cavotricuspid isthmus, left atrium roof, left
atrium bottom, mitral valve isthmus, and complex fractionated
atrial electrogram.
Patient follow-up
All patients were hospitalized with continuous rhythm
monitoring for 3 days after the ablation procedure. Prescription
of anti-arrhythmic drugs (AADs) at discharge and in the outpatient
clinic was determined by the patient’s attending physician as
necessary. We directed patients to check their pulse rate and
rhythm 3 times a day and to visit the outpatient clinic if they
experienced a relapse of AF. All patients were scheduled for visits
to the outpatient clinic at 1, 2, 3, 6, 9, and 12 months after ablation
and every 6 months thereafter. An electrocardiogram was obtained
at each visit. Holter electrocardiogram, transthoracic echocardiog-
raphy, and MDCT were performed 3 months after ablation.
Recurrence of AF/atrial tachycardia was deﬁned as recurrent
symptoms and/or documented AF/atrial tachycardia on electro-
cardiogram. A 3-month blanking period after ablation was
employed. Recurrence type was categorized as mentioned earlier.
Table 1
Baseline characteristics.
No recurrence (n = 42) Very late recurrence (n = 21) p-Value
Age (years) 59  10 61  10 0.3562
Male gender, n (%) 37 (88) 15 (71) 0.1968
Height (cm) 169  7 164  8 0.0156*
Weight (kg) 68.2  10.6 67.3  14.1 0.7571
BMI 24.0  3.2 24.9  3.9 0.2962
History, n (%)
Long-standing persistent AF 16 (38) 9 (43) 0.9275
Length of AF (months) 6 [3.0–12.0] 6 [2.0–36.0] 0.1196
Hypertension 17 (40) 14 (67) 0.0905
Diabetes mellitus 4 (9) 4 (19) 0.5036
Dyslipidemia 17 (40) 12 (57) 0.3256
Obesity 13 (31) 9 (43) 0.5131
CHADS2 score 0.62  0.62 1.10  0.89 0.0163*
Laboratory data
C-reactive protein (mg/dL) 0.04 [0.02–0.08] 0.06 [0.03–0.28] 0.0229*
eGFR (mL/min/1.73m2) 78  25 67  20 0.0973
Brain natriuretic peptide (pg/mL) 77 [28–131] 137 [65–231] 0.0253*
Transthoracic echocardiography data
LVDd (mm) 48.0  4.7 47.8  5.1 0.8547
LVDs (mm) 32.2  6.3 31.7  6.2 0.7456
LAD (mm) 38.8  4.8 40.2  3.5 0.2275
LVEF (%) 61  12 62  12 0.9168
Mitral annulus velocity (cm/s) 9.5  3.0 9.7  3.4 0.8386
Computed tomography data
LAMaxV (mL) 73.6 [59.0–93.9] 93.4 [76.5–105.3] 0.0725
LAMinV (mL) 60.5 [48.4–81.8] 75.7 [60.6–88.8] 0.0383*
LAEF (%) 16.4 [13.2–22.6] 15.6 [11.3–19.4] 0.1967
AAD prescription, n (%) 13 (31) 12 (57) 0.0837
Follow-up period (years) 2.9  1.4 3.9  1.4 0.0177*
Data are expressed as mean + SD, as n (%), or as median [interquartile range].
AF, atrial ﬁbrillation; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic
diameter; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LAMaxV, left atrial maximum volume; LAMinV, left atrial minimum volume; LAEF, left atrial
emptying fraction; AAD, anti-arrhythmic drugs.
* p < 0.05.
Table 2
Catheter ablation procedure.
No recurrence
(n = 42)
Very late
recurrence (n = 21)
p-Value
Pulmonary vein isolation 42 (100) 21 (100) –
Linear ablation of
Cavotricuspid isthmus 24 (57) 13 (62) 0.9279
Roof of the left atrium 22 (52) 13 (62) 0.654
Base of the left atrium 4 (10) 2 (10) 0.6489
Mitral valve isthmus 14 (33) 7 (33) 0.7768
Complex fractionated
atrial electrogram
7 (17) 8 (38) 0.1167
Isolation of superior vena cava 1 (2) 2 (10) 0.5303
Data are expressed as n (%).
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A pre-study power analysis indicated that a sample size of
56 patients was necessary (a = 0.05, power = 0.8) to detect a 15%
difference in the reduction rate of LA volume between both the
groups, which was considered the smallest relevant difference
[15]. Continuous variables with normal distributions are expressed
as mean  standard deviation and those with unequal variance as
median and interquartile range (25th, 75th percentile). Categorical
variables are expressed as numbers and frequencies. Group means
for continuous variables with normal and non-normal distributions
were compared using Student’s t-test and Mann–Whitney U test,
respectively. Categorical variables were compared using x2 test or
Fisher’s exact test, as appropriate. Receiver operating characteristic
(ROC) curves were generated to obtain the area under the ROC curve
(AUC) values with 95% conﬁdence intervals (CI), along with the
sensitivity and speciﬁcity of each CT variable as a predictor of VLR. All
statistical analyses were performed using MedCalc (ver. 12.7.5.0;
MedCalc Software, Acacialaan, Ostend, Belgium).
Results
Baseline characteristics
We identiﬁed 63 patients (52 males) aged 60  10 years, of
whom 21 experienced VLR. We followed them for a mean of
3.2  1.5 years. The preoperative demographic data are summarized
in Table 1. CHADS2 score, hsCRP and BNP levels, and LAMinV were
signiﬁcantly higher in the VLR group than in the NR group. Other
demographic factors were similar in both the groups. AAD prescrip-
tion rate was also assessed, and no signiﬁcant differences were foundbetween the groups [NR vs. VLR, 13/42 (31%) vs. 12/21 (57%),
p = 0.0837].
CA procedure
Table 2 shows the differences in RFCA procedures between
both the groups. We successfully performed PV isolation in all
patients. There was no signiﬁcant difference in the frequency of
other procedures; linear ablation of the cavotricuspid isthmus,
roof and bottom of the left atrium, and mitral valve isthmus,
complex fractionated atrial electrogram; and isolation of the
superior vena cava.
MDCT parameters and reverse remodeling
After successful RFCA, LAMaxV was reduced in the NR group
but not in the VLR group (Fig. 1A) [NR vs. VLR, 79  29 mL to
Fig. 1. (A) Impact of catheter ablation on left atrial maximum volume. After successful catheter ablation, left atrial maximum volume (LAMaxV) was reduced in the no-
recurrence (NR) group but not in the very late recurrence (VLR) group; NR vs. VLR, 79  29 mL to 57  19 mL (p < 0.0001) vs. 94  31 mL to 89  37 mL (p = 0.2645). (B) Impact of
catheter ablation on left atrial minimum volume. After successful catheter ablation, left atrial minimum volume (LAMinV) was reduced in both the NR and VLR groups; NR vs. VLR,
64  25 mL to 35  14 mL (p < 0.0001) vs. 79  31 mL to 64  38 mL (p = 0.0026). (C) Impact of catheter ablation on left atrial emptying fraction. After successful catheter ablation,
left atrial emptying fraction (LAEF) was improved in both the NR and VLR groups; NR vs. VLR, 20  13% to 38  12% (p < 0.0001) vs. 16  7% to 31  13% (p < 0.0001).
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LAMinV was reduced in both the groups (Fig. 1B) [NR vs. VLR,
64  25 mL to 35  14 mL (p < 0.0001) vs. 79  31 mL to 64  38 mL
(p = 0.0026)]. LAEF was improved in both the groups after sinus
conversion (Fig. 1C) (NR vs. VLR, 20  13% to 38  12% [p < 0.0001]
vs. 16  7% to 31  13% [p < 0.0001]). The rate of LAMaxV andLAMinV reduction is shown in Fig. 2. Compared with patients in
the NR group, those in the VLR group demonstrated poor LA reverse
remodeling [LAMaxV reduction rate: NR vs. VLR, mean 25.4%
(95% conﬁdence interval (CI), 19.6–31.3%) vs. 5.4% (3.0–13.7%);
LAMinV reduction rate: mean 39.5% (32.0–47.1%) vs. 20.7%
(9.3–32.1%)].
Fig. 2. Reduction rate of left atrial maximum and minimum volume. Compared with patients in the no-recurrence (NR) group, those in the very late recurrence (VLR) group
demonstrated poor left atrial reverse remodeling. Reduction rate of left atrial maximum volume (LAMaxV): NR vs. VLR, mean 25.4% (95% CI, 19.6–31.3%) vs. 5.4% (3.0 to
13.7%); reduction rate of left atrial minimum volume (LAMinV): 39.5% (32.0–47.1%) vs. 20.7% (9.3–32.1%).
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AUC analysis was performed to determine the best cut-off
values for perioperative MDCT data in the prediction of VLR.
We compared 6 ROC curves (LAMaxV reduction rate, LAMinV
reduction rate, Pre-LAMaxV, Pre-LAMinV, Post-LAMaxV, and Post-
LAMinV) using AUC comparison analysis (Fig. 3). The highest
AUC was obtained with post-LAMinV [AUC, 0.828 (95% CI, 0.712–
0.912), p < 0.0001], with a best cut-off value of 44 mL (sensitivity
81.0%, speciﬁcity 81.0%). Higher post-LAMinV was associated
with higher VLR risk [hazard ratio = 1.0168 (95% CI, 1.0074–
1.0263), p = 0.0005].Fig. 3. Comparison of MDCT parameters for VLR prediction. We compared six ROC
curves (LAMaxV reduction rate, LAMinV reduction rate, Pre-LAMaxV, Pre-LAMinV,
Post-LAMaxV, and Post-LAMinV). The highest AUC was obtained with post-LAMinV
[AUC; 0.828 (95% CI, 0.712–0.912), p < 0.0001] with a best cut-off value of 44 mL
(sensitivity 81.0%, speciﬁcity 81.0%). MDCT, multidetector computed tomography;
VLR, very late recurrence; ROC curve, receiver operating characteristic curve;
LAMaxV, left atrial maximum volume; LAMinV, left atrial minimum volume; AUC,
area under the ROC curve.Discussion
Main ﬁndings
Post-LAMinV was most signiﬁcantly associated with higher VLR
risk among the tested perioperative MDCT parameters. Post-
LAMinV represents a potential marker for evaluating the long-term
effectiveness of CA, even in patients with initially successful RFCA.
Persistent LA structural remodeling after initially successful RFCA
for non-paroxysmal AF may be an important risk factor for VLR.
LA reverse remodeling of patients with initially successful RFCA
LA reverse remodeling has been previously demonstrated after
initially successful RFCA. In contrast, progressive LA remodeling
was observed in those with AF recurrences after RFCA [16,17]. A
recent meta-analysis also arrived at the same conclusion [14].
However, our results indicated that some patients with initial
success (within 1 year after RFCA) did not experience LA reverse
remodeling at 3-month follow-up and that this patient cohort
was at high VLR risk. In previous studies, this cohort would have
been identiﬁed as having successful RFCA, because of their short
follow-up periods. The present study suggested that poor reverse
remodeling was a predictor of VLR. Long-term follow-up is
desirable for those with insufﬁcient LA reverse remodeling.
Possible mechanisms underlying poor reverse remodeling
Various mechanisms can lead to a reduction in LA size following
RFCA. Reverse remodeling due to a decreased AF burden and
shrinkage due to ablation-induced ﬁbrosis are probably the most
likely causes [10,18].
In the present study, all participants were free from AF burden
during the ﬁrst year after the initial procedure. Therefore, reverse
remodeling due to decreased AF burden could have occurred in all
patients. To evaluate the impact of ablation-induced ﬁbrosis on the
study outcomes, we analyzed the differences in RFCA procedures
between the NR and VLR groups. However, there were no
signiﬁcant differences between the groups, indicating that the
effect of ablation-induced ﬁbrosis was probably similar.
Considering the baseline population characteristics, hsCRP and
BNP levels were signiﬁcantly higher in the VLR group than in the
NR group. We previously reported that hsCRP levels were
signiﬁcantly higher in the VLR group than in the NR group [7];
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reported—hsCRP levels may be indicative of LA myocardial
inﬂammation. An increase in the levels of BNP, which is secreted
by the ventricles of the heart in response to excessive stretching of
the cardiomyocytes, implies increased LA wall stress. These factors
could promote LA ﬁbrosis and prevent LA reverse remodeling.
Difﬁculty in RFCA for hypertrophied hearts reported by Mu¨ssig-
brodt et al. is compatible with this result [19]. Another possible
factor is autonomic nerve activity, although this was not directly
evaluated in the present investigation. Fujino et al. reported that in
symptomatic younger AF patients (age 40 years), a low BMI
was an independent clinical factor for unsuccessful AF ablation
outcomes [20]. They described a theory that slender patients have
higher autonomic nerve activity than obese patients, and this
might be more signiﬁcant in younger patients than elderly
patients. Although in our study there was no difference in BMI
between the groups, patients with NR were taller than those with
VLR. The difference of physical constitution could presumably
cause the difference of autonomic nerve activity.
Pre-RFCA LAMinV was also higher in the VLR group than in the
NR group. Some patients with enlarged LA might have irreversible
LA ﬁbrosis, although magnetic resonance imaging was not
performed in this study. Recent data have suggested that LA
ﬁbrosis detected by magnetic resonance imaging independently
and strongly predicts the outcome of ablation in patients with AF
[21,22]. If LA ﬁbrosis progressed markedly, even successful RFCA
could not cause LA reverse remodeling.
In summary, as previously reported, decreased AF burden and
shrinkage due to ablation-induced ﬁbrosis can promote LA reverse
remodeling. On the contrary, the present study suggested that pre-
procedural irreversible LA ﬁbrosis, LA myocardial inﬂammation,
and increased LA wall stress could prevent LA reverse remodeling.
Given the short MDCT follow-up period, pre-procedural irrevers-
ible LA ﬁbrosis may be the major mechanism preventing LA reverse
remodeling and represent the arrhythmogenic substrate for VLR.
Clinical implication
This study implied that patients with residual remodeling after
AF ablation might have irreversible LA ﬁbrosis that could be a
substrate of AF. In these patients, VLR could easily occur because of
the residual AF substrate and progression of the substrate promoted
by post-RFCA inﬂammation and LA wall stress, despite successfully
eliminating AF.
We believe that our ﬁndings have the following clinical
implications: (1) it is important to evaluate the extent of pre-
procedural LA ﬁbrosis in patients with LA remodeling, (2) the
indication for RFCA needs to be considered with care in patients
with advanced LA ﬁbrosis, and (3) we need to perform careful
follow-up for those with residual LA remodeling after RFCA, even in
the absence of clinical AF recurrence.
Limitations
The present study had several limitations. First, there is difﬁculty
associated with detecting asymptomatic AF recurrence; therefore,
the recurrence rate could have been underestimated. Some patients
in the NR group may have experienced AF recurrence, and some
in the VLR group may have experienced ER and LR. Second, it
is possible that AADs prolonged the time to AF recurrence and
changed ER and LR into VLR. To evaluate this, we analyzed the AAD
prescription rate at discharge and found no signiﬁcant differences
between the groups. Third, the follow-up period was 1 year longer in
the VLR group than in the NR group, indicating that some patients in
the NR group could develop VLR in the future. To eliminate this
limitation, we re-evaluated patients in the VLR group with a 1-yearshorter follow-up period; although 5 patients were excluded in this
analysis, the results were more or less comparable with the main
results of this study. Fourth, MDCT as the re-evaluation method of LA
structural remodeling after AF ablation has the demerit of exposure
to radiation. Less invasive methods such as 3D echocardiography can
be an alternative method to avoid exposure to radiation in the future.
Finally, this was a single-center, retrospective, case–control
study. Therefore, some patients were excluded as we could not
follow them, which may have resulted in a selection bias. In addition,
the study cohort was small, although an appropriate power analysis
was performed.
Conclusions
Of the perioperative parameters assessed, higher post-LAMinV
was most signiﬁcantly associated with higher VLR risk. Persistent
LA structural remodeling after initially successful CA for non-
paroxysmal AF may be an important risk factor for VLR.
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